Css LLC Il lowered its stake in Cencora, Inc. (NYSE:COR - Free Report) by 65.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,238 shares of the company's stock after selling 2,350 shares during the quarter. Css LLC Il's holdings in Cencora were worth $278,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. PharVision Advisers LLC acquired a new position in shares of Cencora during the 4th quarter worth approximately $453,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Cencora by 6.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,648,451 shares of the company's stock valued at $370,374,000 after buying an additional 96,238 shares in the last quarter. Waverly Advisors LLC acquired a new position in Cencora during the fourth quarter worth $232,000. Worldquant Millennium Advisors LLC raised its position in Cencora by 42.4% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 385,759 shares of the company's stock worth $86,672,000 after acquiring an additional 114,806 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in Cencora during the fourth quarter worth $1,113,000. Institutional investors own 97.52% of the company's stock.
Cencora Price Performance
Cencora stock opened at $290.03 on Friday. The company has a market capitalization of $56.21 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 1.31 and a beta of 0.60. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $309.35. The stock's 50 day moving average is $281.86 and its 200-day moving average is $256.65.
Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $3.80 EPS. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.
Insider Buying and Selling at Cencora
In related news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares in the company, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,223 shares of company stock valued at $12,369,767 in the last quarter. Company insiders own 10.80% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently commented on COR. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Wells Fargo & Company raised their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Robert W. Baird lifted their price target on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. UBS Group boosted their price target on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Evercore ISI raised their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $301.18.
Check Out Our Latest Report on COR
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
